Post-COVID-19 Burden of Severe Influenza in England Among Overall Population and High-Risk Groups: Results From the INFORM Study, 2022–2023
Open Access
- 27 March 2026
- journal article
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (5) , 1401-1424
Abstract
We describe the burden of severe influenza in England overall, and in risk groups (as defined by age, immunocompromise, and other comorbidities) and those with recent COVID-19. The INFORM (INvestigation oF cOvid-19 Risk among iMmunocompromised populations) cohort uses pseudonymised, routinely collected electronic health records of individuals aged ≥ 12 years from a random 25% sample of England's population (N = 12.1 million). In this analysis, during 1 July 2022 to 30 June 2023, crude incidence rates (IRs) and age- and sex-adjusted IR ratios were estimated for severe influenza outcomes of hospitalisation, intensive care unit (ICU) admission and death. The analyses were repeated for outcomes of severe influenza with recent COVID-19 (< 6 months). The analysis sample comprised 12,075,920 individuals aged ≥ 12 years; 3.9% were immunocompromised. Overall, IRs of severe influenza were 10.51 (hospitalisations), 0.35 (ICU admissions) and 0.73 (deaths) per 10,000 person-years. Of those with influenza hospitalisation, 13.1% had recent COVID-19. Overall, influenza hospitalisation IRs per 10,000 person-years increased with advancing age, from 3.56 for adolescents aged 12-17 years to 58.43 for adults aged ≥ 80 years. Compared with other age groups, among hospitalised individuals, the highest intensity of management occurred in adolescents aged 12-17 years, based on the proportion of influenza hospitalisations that involved ICU admission (6.2%) or mechanical ventilation (3.0%) in this age group. Increased age- and sex-adjusted risk of severe influenza outcomes was observed among individuals with immunocompromise and other comorbidities. Seasonal severe influenza was observed in the general population aged ≥ 12 years in England in 2022-2023, with a disproportionately higher burden recorded in risk groups (as defined by age, immunocompromise, recent COVID-19 and other comorbidities). These data reinforce continued efforts to immunise individuals against seasonal influenza. International Standard Randomised Controlled Trial Number Registry: ISRCTN53375662.Keywords
Funding Information
- AstraZeneca
This publication has 28 references indexed in Scilit:
- Increasing child vaccination coverage can reduce influenza cases across age groups: An agent-based modeling studyJournal of Infection, 2025
- Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM studyJournal of Infection, 2025
- Categorising interventions to enhance vaccine uptake or reduce vaccine hesitancy in the United Kingdom: A systematic review and meta-analysisVaccine, 2024
- Validity of ICD‐10‐based algorithms to identify patients with influenza in inpatient and outpatient settingsPharmacoepidemiology and Drug Safety, 2024
- Estimating the prevalence of immunocompromising conditions and primary immunodeficiency disorders in the Chinese populationJournal of Infection, 2023
- Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM studyThe Lancet Regional Health - Europe, 2023
- Clinical perspectives on the age-related increase of immunosuppressive activityJournal of Molecular Medicine, 2022
- Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017The Lancet Respiratory Medicine, 2019
- The burden of influenza in England by age and clinical risk group: A statistical analysis to inform vaccine policyJournal of Infection, 2014
- Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responsesThe Lancet Infectious Diseases, 2009